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Background: Long-term effect of ezetimibe-statin therapy on low-density lipoprotein cholesterol (LDL-C) lowering including cholesterol absorption 
and synthesis remains unclear.
Methods: We performed a multi-center, prospective, randomized trial involving 86 coronary artery disease patients who could not attain LDL-
C<100mg/dl despite treatment with atorvastatin 10mg or rosuvastatin 2.5mg (initial dose in Japan). Patients were assigned to an addition of 
ezetimibe 10mg to statins (ES: n=44) or double dose of statins (DS: n=42) for 52 weeks. We measured lipid profile including campesterol/total 
cholesterol (TC) (as an absorption marker) and lathosterol/TC (as a synthesis marker).
Results: Baseline patient’s characteristics did not differ between ES and DS.
The reduction in LDL-C at 12 weeks was greater in ES than DS (-34±14 vs -24±14 mg/dl, p<0.01) and the difference maintained through 52 weeks.
Although campesterol/TC level significantly decreased from baseline to 12 weeks and maintained afterward in ES, it increased over time in DS.
Although lathosterol/TC level increased from baseline to 12 weeks, it did not afterward in ES. On the other hand, lathosterol/TC level decreased from 
baseline to 12 weeks but it increased afterward in DS.
Conclusions: Ezetimibe-statin therapy provided higher LDL-C reduction compared with statin monotherapy up to 52 weeks. Although cholesterol 
absorption was inhibited until 52 weeks after in ezetimibe-statin therapy, it increased over time in statin monotherapy.
